Share:
Commercial Launch of VAZKEPA in Europe on Track to Commence in Q3 2021 Following Recent Market Authorization with VASCEPA® Growth in the United States Positioned to Increase as the Impact of COVID-19 Recedes
Expenses Managed in Q1 2021 to Minimize Operating Loss Despite Revenue Impact of COVID-19 and Other Factors
Management to Host Conference Call Today at 7:30 a.m. ET
DUBLIN, Ireland and BRIDGEWATER, N.J., April 29, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended March 31, 2021 and provided an update on company operations.
Recent Key Amarin Highlights:
Q1 net total revenue
: Net total revenue in the first quarter of 2021 was $142.2 million, consisting of $140.8 million in net product revenue from the United States, $0.5 million in net product revenue from outside the United States and $0.8 million in licensing and royalty revenue. Net product revenue from the United States declined $4.7 million,
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
April 22, 2021 10:53 ET | Source: Amarin Corporation plc Amarin Corporation plc Bedminster, New Jersey, UNITED STATES
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication
1,2,
VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorization for VAZKEPA (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascul
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and .
Amarin Corporation plcApril 22, 2021 GMT
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication
1,2,
VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorization for VAZKEPA (icosapent ethyl) as a treatment to reduce the risk of cardiovascular events in high cardiovascular risk statin-treated adult patients who have elevated triglycerides (≥150 mg/dL) and either established cardiovascular disease or diabetes, and at least one additional cardiovascular risk factor
Billionaire Steve Cohen’s Top 10 Small-Cap Stock Picks
Steve A. Cohen is the owner of Point72 Asset Management, one of the most successful hedge funds in the U.S. He started off his Wall Street career as a junior trader at Gruntal & Co., where he dealt with options arbitrage. Cohen started his first hedge fund known as S.A.C. Capital Advisors in 1992, enjoying some success which allowed him to own 8 percent of Major League Baseball team, the New York Mets. He has also been involved in philanthropic causes in which he contributed $715 million.
Unfortunately, SAC Capital was allegedly involved in an insider trading scandal which led to a hefty $1.8 billion fine, and Cohen had to shut down the fund. This pave the way for the birth of his current hedge fund.
vimarsana © 2020. All Rights Reserved.